Evidence map›Paper›PMID 35481021›Full record

ArticleRSC advances2021

A new solvate of clonixin and a comparison of the two clonixin solvates.

Yunping Zhoujin, Mingtao Zhang, Sean Parkin, Tonglei Li, Faquan Yu, Sihui Long

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Yunping ZhoujinKey Laboratory for Green Chemical Process of Ministry of Education, Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, Hubei Engineering Research Center for Advanced Fine Chemicals, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology 206 1st Rd Optics Valley, East Lake New Technology Development District Wuhan Hubei 430205 China fyuwucn@gmail.com longsihui@yahoo.com Sihuilong@wit.edu.cn +86 27 87194980.
Mingtao ZhangComputational Center for Molecular Science, College of Chemistry, Nankai University Tianjin China.ORCID https://orcid.org/0000-0001-9588-9751
Sean ParkinDepartment of Chemistry, University of Kentucky Lexington Kentucky 40506 USA.ORCID https://orcid.org/0000-0001-5777-3918
Tonglei LiDepartment of Industrial and Physical Pharmacy, Purdue University West Lafayette Indiana 47907 USA.ORCID https://orcid.org/0000-0003-2491-0263
Faquan YuKey Laboratory for Green Chemical Process of Ministry of Education, Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, Hubei Engineering Research Center for Advanced Fine Chemicals, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology 206 1st Rd Optics Valley, East Lake New Technology Development District Wuhan Hubei 430205 China fyuwucn@gmail.com longsihui@yahoo.com Sihuilong@wit.edu.cn +86 27 87194980.ORCID https://orcid.org/0000-0002-5062-8731
Sihui LongKey Laboratory for Green Chemical Process of Ministry of Education, Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, Hubei Engineering Research Center for Advanced Fine Chemicals, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology 206 1st Rd Optics Valley, East Lake New Technology Development District Wuhan Hubei 430205 China fyuwucn@gmail.com longsihui@yahoo.com Sihuilong@wit.edu.cn +86 27 87194980.ORCID https://orcid.org/0000-0002-4424-6374
Green Chemistry · PLNankai University · CNPurdue University West Lafayette · USUniversity of Kentucky · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new solvate of clonixin (CLX), a dimethylacetamide (DMA) solvate, has been obtained by crystal growth in DMA. The new form was characterized by NMR, single-crystal X-ray diffraction, and PXRD. The crystal structure is stabilized by a strong hydrogen bond between the carboxylic acid OH of CLX and the DMA carbonyl, the strength of which is on par with those of the four solvent-free forms of CLX and the DMF solvate. These previously known forms are based on either the acid-acid homosynthon or the acid-pyridine heterosynthon, depending on the dihedral angle between the two aromatic rings of CLX, or the heterodimer between CLX and DMF. The new solvate loses DMA to convert into form I of CLX, as confirmed by differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD), similar to how the DMF solvate does. A comparison of the two solvates was carried out and theoretical studies were performed to shed light on the conformational difference between the two CLX molecules in the two solvates and the packing differences between them. The insight gained on this solvatomorphic system could aid the design of new solvates and cocrystals of CLX.

Identifiers

PMID35481021
PMCPMC9036871
OpenAlexW3184378632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.